Wolf D - Search Results

1

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.

Thielen N, Richter J, Baldauf M, Barbany G, Fioretos T, Giles F, Gjertsen BT, Hochhaus A, Schuurhuis GJ, Sopper S, Stenke L, Thunberg S, Wolf D, Ossenkoppele G, Porkka K, Janssen J, Mustjoki S. Thielen N, et al. Among authors: wolf d. Clin Cancer Res. 2016 Aug 15;22(16):4030-8. doi: 10.1158/1078-0432.CCR-15-2791. Epub 2016 Mar 22. Clin Cancer Res. 2016. PMID: 27006491

2

The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C. Wolf D, et al. Among authors: wolf am. Clin Cancer Res. 2005 Dec 1;11(23):8326-31. doi: 10.1158/1078-0432.CCR-05-1244. Clin Cancer Res. 2005. PMID: 16322292

3

Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia.

Schmidt S, Gastl G, Wolf D. Schmidt S, et al. Among authors: wolf d. Leuk Lymphoma. 2008 Apr;49(4):643-7. doi: 10.1080/10428190801896194. Leuk Lymphoma. 2008. PMID: 18398726 Review.

4

Role of gene-expression profiling in chronic myeloid leukemia.

Schmidt S, Wolf D. Schmidt S, et al. Among authors: wolf d. Expert Rev Hematol. 2009 Feb;2(1):93-103. doi: 10.1586/17474086.2.1.93. Expert Rev Hematol. 2009. PMID: 21082998 Review.

5

Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?

Rudzki J, Wolf D. Rudzki J, et al. Among authors: wolf d. Expert Rev Hematol. 2011 Apr;4(2):153-9. doi: 10.1586/ehm.11.9. Expert Rev Hematol. 2011. PMID: 21495925

6

DyeCycle Violet used for side population detection is a substrate of P-glycoprotein.

Boesch M, Reimer D, Rumpold H, Zeimet AG, Sopper S, Wolf D. Boesch M, et al. Among authors: wolf d. Cytometry A. 2012 Jun;81(6):517-22. doi: 10.1002/cyto.a.22038. Epub 2012 Mar 7. Cytometry A. 2012. PMID: 22407964 Free article.

7

Advances in immunotherapy of chronic myeloid leukemia CML.

Held SA, Heine A, Mayer KT, Kapelle M, Wolf DG, Brossart P. Held SA, et al. Curr Cancer Drug Targets. 2013 Sep;13(7):768-74. doi: 10.2174/15680096113139990086. Curr Cancer Drug Targets. 2013. PMID: 23906051 Review.

8

Systematic assessment of decision-analytic models for chronic myeloid leukemia.

Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, Radich J, Brixner D, Gastl G, Siebert U. Rochau U, et al. Among authors: wolf d. Appl Health Econ Health Policy. 2014 Apr;12(2):103-15. doi: 10.1007/s40258-013-0071-8. Appl Health Econ Health Policy. 2014. PMID: 24385259 Review.

9

MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure.

Agrawal M, Hanfstein B, Erben P, Wolf D, Ernst T, Fabarius A, Saussele S, Purkayastha D, Woodman RC, Hofmann WK, Hehlmann R, Hochhaus A, Müller MC. Agrawal M, et al. Among authors: wolf d. Leukemia. 2014 Jul;28(7):1478-85. doi: 10.1038/leu.2014.6. Epub 2014 Jan 10. Leukemia. 2014. PMID: 24472814

10

The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics.

Boesch M, Zeimet AG, Reimer D, Schmidt S, Gastl G, Parson W, Spoeck F, Hatina J, Wolf D, Sopper S. Boesch M, et al. Among authors: wolf d. Oncotarget. 2014 Aug 30;5(16):7027-39. doi: 10.18632/oncotarget.2053. Oncotarget. 2014. PMID: 25216521 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,856 results

Search Page